Advertisement for orthosearch.org.uk
Results 1 - 1 of 1
Results per page:
Applied filters
General Orthopaedics

Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 94-B, Issue SUPP_XXI | Pages 25 - 25
1 May 2012
Y-M. K S. G D. S A. K P. M H.S. G D M
Full Access

Pseudotumours (soft-tissue masses relating to the hip joint) following metal-on-metal hip resurfacing arthroplasty (MoMHRA) have been associated with elevated serum and hip aspirate metal ion levels, suggesting that pseudotumours occur when there is increased wear. This study aimed to quantify the wear of implants revised for pseudotumours and a control group of implants revised for other reasons of failure.

A total of 30 contemporary MoMHRA implants in two groups were investigated: (1) 8 MoMHRA implants revised due to pseudotumour; (2) 22 MoMHRA implants revised due to other reasons of failure. The linear wear of retrieved implants was measured using a Taylor-Hobson Roundness machine. The average linear wear rate was defined as the maximum linear wear depth divided by the duration of the implant in vivo.

In comparison with the non-pseudotumour implant group, the pseudotumour implant group was associated with: (1) significantly higher median linear wear rate of the femoral component: 8.1 um/year (range 2.75-25.4 um/year) vs. 1.97 um/year (range 0.82-13.00 um/year), p=0.002; and (2) significantly higher median linear wear rate of the acetabular component: 7.36 um/year (range 1.61-24.9 um/year) vs. 1.28 um/year (range 0.18-3.33 um/year), p=0.001. Wear on the acetabular cup components in the pseudotumour group always involved the edge, indicating edge-loading of the bearing.

Significantly greater linear wear rates of the MoMHRA implants revised due to pseudotumour support the in vivo elevated metal ion concentrations in patients with pseudotumours. This study is the first to confirm that pseudotumour occurs when there is increased wear at the MoM articulation. Furthermore, edge-loading may be the dominant wear generation mechanism in patients with pseudotumour.